Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019.
Kristian Løkke FunckJakob Schöllhammer KnudsenTroels Krarup HansenReimar Wernich ThomsenErik Lerkevang GrovePublished in: Diabetes, obesity & metabolism (2020)
In patients with T2DM and CVD, the incidence of cardioprotective GLD initiation increased between 2012 and 2018, however, within 2 years of dual diagnosis, it remained low.